摘要
目的:探讨重组人红细胞生成素(recombinant human erythropoietin,rhEPO)纠正胃癌患者术前贫血的临床疗效,以尽可能减少异体输血。方法:2002-01-01-2004-12-31期间114例经手术治疗的胃癌患者中术前出现贫血(Hb<110 g／L,Hct<0．3,下同)的46例(40．4％)患者,随机分为研究组和对照组各23例。研究组在手术前后分别给予rhEPO1×104U,皮下注射,隔日1次,共6次,同时口服琥珀酸亚铁;对照组除按常规输异体血外,未作其他处理。结果:对照组中有21例在围手术期作了输血治疗,平均输异体血1 150 mL;研究组12例输入异体血,平均输血600 mL。研究组无术后并发症;对照组有4例出现术后并发症。同时研究显示,研究组手术当日Hb<90 g／L和Hct<0．3的病例数比对照组显著减少。结论:应用rhEPO可以减少异体输血,并使患者较平稳地度过围手术期。
Objective： To investigate the clinical efficacy of recombinant human erythropoietin （rhEPO） in treatment of preoperative anemia in patients with gastric cancer, so as to reduce allogeneic blood transfusion. Methods： From January 2002 to December 2004, 114 patients underwent operation of gastric cancer. Of them, 46 were diagnosed to have preoperative anemia （Hb〈110 g/L, Hct〈0. 3, accounted for 40.4%）. The 46 cases were randomly divided into study group and control group. Twenty-three cancer patients in the study group received rhEPO 1 × 10^4 U hypodermic/qod, for 6 times, and took ferrous citrate orally at the same time. And 23 patients （control group） only received allogeneic blood transfusion. Results：Twenty-one cases in control group received allogeneic blood transfusion in preoperative period, the average quantity was 1 150 mL. And in study group there were 12 patients received allogeneic blood transfusion and the average quantity transfused was 600 mL. Complications occurred in 4 cases of the control group, but not in the study group. In study group, the cases with Hb〈90 g/L and Hct〈0.3 on the operation day were less than those in the control group. Conclusion： After treatment with rhEPO, the allogeneic blood transfusion can be reduced, and the safety during perioperative period can be improved.
出处
《药学服务与研究》
CAS
CSCD
2006年第5期355-357,共3页
Pharmaceutical Care and Research
基金
上海市青浦区科委2003-2006年度科技发展基金(青科发2003-57)
关键词
红细胞生成素
重组
胃肿瘤
贫血
手术期间
输血
异体
erythropoietin, recombinant
stomach neoplasms
anemia
intraoperative period
blood transfusion, allogeneic
